Plain-English translation of NCT04535882 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are studying a protein called leucine-rich alpha-2 glycoprotein (LRG) found in blood to see if it can help measure how severe ulcerative colitis or Crohn's disease inflammation is in the colon. When you have IBD, doctors currently use endoscopy (a camera test) and clinical scoring systems to assess disease activity. This study will compare blood levels of this protein to those results to learn if this protein could become a simpler, non-invasive way to track your disease.
Currently, doctors must use invasive procedures like colonoscopy to check how active IBD is in your colon. If this medication or blood marker could reliably measure disease activity without a procedure, it would help doctors monitor your condition more easily and catch flare-ups sooner.
You likely qualify if…
You likely don't qualify if…
You will have a blood sample drawn and undergo a colonoscopy with tissue biopsies. These procedures should be done within 7 days of each other. Your doctor will also review your medical records to score how active your disease is using standard clinical tools. The study will then compare your blood protein levels to these disease activity scores to see if the protein is a useful marker.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
Japan
Enrollment target
~300 participants
Started
October 2020
Primary completion
December 2026
Last updated on clinicaltrials.gov in May 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Akira Horiuchi, MD
Showa Inan General Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.